Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,689 | $2,708 | $2,469 | $2,469 |
| - Cash | $142 | $374 | $241 | $409 |
| + Debt | $2 | $5 | $8 | $2 |
| Enterprise Value | $1,549 | $2,339 | $2,237 | $2,062 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$263 | -$188 | -$135 | -$237 |
| % Margin | – | – | – | – |
| Net Income | -$244 | -$236 | -$131 | -$237 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.53 | -1.49 | -0.86 | -1.56 |
| % Growth | -2.7% | -73.3% | 44.9% | – |
| Operating Cash Flow | -$183 | -$163 | -$115 | -$75 |
| Capital Expenditures | $0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$183 | -$163 | -$115 | -$76 |